EKSO (Ekso Bionics Holdings) Notes Receivable: $0.00 Mil (As of Mar. 2026)


EKSO Ekso Bionics Holdings Inc EKSO
32 GF Score
Price $11.65
GF Value $4.36
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Ekso Bionics Holdings Notes Receivable?

Ekso Bionics Holdings EKSO -0.42% 32 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates EKSO with a GF Score™ of 32/100 and a GF Value™ of $4.36 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Ekso Bionics Holdings's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Ekso Bionics Holdings Notes Receivable Related Terms

Ekso Bionics Holdings Notes Receivable Historical Data

* Premium members only.

The historical data trend for Ekso Bionics Holdings's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ekso Bionics Holdings Notes Receivable Chart

Ekso Bionics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Ekso Bionics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
EKSO
32GF Score
Ekso Bionics Holdings Inc EKSO
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ekso Bionics Holdings Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Ekso Bionics Holdings (EKSO) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ekso Bionics Holdings and its competitors.
Is Ekso Bionics Holdings' Notes Receivable too high?
Ekso Bionics Holdings' current Notes Receivable is $0.00 Mil. Overall, Ekso Bionics Holdings has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ekso Bionics Holdings' Notes Receivable compare to POCI and HBIO?
Ekso Bionics Holdings' Notes Receivable of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Devices & Instruments company?
A good Notes Receivable depends on the Medical Devices & Instruments industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Ekso Bionics Holdings and its competitors. Ekso Bionics Holdings's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ekso Bionics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ekso Bionics Holdings (EKSO) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.36, compared to a current price of $11.65 — trading 167.2% above its estimated fair value. The current Notes Receivable is $0.00 Mil. Ekso Bionics Holdings' overall GF Score™ is 32/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Ekso Bionics Holdings (EKSO), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ekso Bionics Holdings (EKSO) Overvalued in 2026?

Based on GuruFocus' analysis, Ekso Bionics Holdings stock appears to be overvalued. The current stock price of $11.65 is trading 167.2% above its estimated GF Value™ of $4.36. GuruFocus considers Ekso Bionics Holdings to be Significantly Overvalued.

Key valuation signals for EKSO:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $4.36 vs. price of $11.65 (167.2% above fair value)
  • GF Score™: 32/100 with 10 warning signs

No single metric tells the full story. See the EKSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ekso Bionics Holdings Business Description

Address 101 Glacier Point, Suite A, San Rafael, CA, USA, 94901
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
32GF Score

Get the complete analysis for EKSO

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.65
Price
$4.36
GF Value